Subscribe
nobeastsofierce / Shutterstock.com
12 November 2024NewsEuropeMarisa Woutersen

CRISPR patents revoked following Nobel Prize winners’ withdrawal

The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows unfavourable preliminary opinion from the EPO | Cancelled patents not expected to impact ongoing licensing agreements for CRISPR technology, says licensor.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards
27 September 2024   A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Europe
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards
27 September 2024   A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.

More on this story

Europe
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards
27 September 2024   A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.

More features

Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact